Stockscreener 앱 받기
0.5202
32.71%
-0.2529
시장 영업 전:
.53
0.0098
+1.88%
전일 마감가:
$0.7731
열려 있는:
$0.722
하루 거래량:
4.08M
Relative Volume:
3.31
시가총액:
$10.13M
수익:
-
순이익/손실:
$-30.33M
주가수익비율:
-0.0186
EPS:
-28.0369
순현금흐름:
$-24.28M
1주 성능:
-32.89%
1개월 성능:
-12.28%
6개월 성능:
-74.75%
1년 성능:
-94.83%
1일 변동 폭
$0.5004
$0.733
1주일 범위
$0.5004
$0.8175
52주 변동 폭
$0.1614
$15.75
Moleculin Biotech Inc Stock (MBRX) Company Profile
명칭
Moleculin Biotech Inc
전화
713-300-5160
주소
5300 MEMORIAL DRIVE, HOUSTON, TX
Compare MBRX vs VRTX, REGN, MRNA, ARGX, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MBRX
Moleculin Biotech Inc
|
0.5202 | 13.93M | 0 | -30.33M | -24.28M | -28.04 |
VRTX
Vertex Pharmaceuticals Inc
|
510.72 | 130.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
798.17 | 80.46B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
172.94 | 57.48B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
988.20 | 61.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
365.67 | 39.20B | 5.76B | 514.49M | 1.10B | 4.4813 |
Moleculin Biotech Inc Stock (MBRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-09 | 재개 | H.C. Wainwright | Buy |
| 2025-02-12 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2022-07-18 | 재개 | Oppenheimer | Outperform |
Moleculin Biotech Inc 주식(MBRX)의 최신 뉴스
Moleculin Biotech at H.C. Wainwright conference: aml hope builds By Investing.com - Investing.com Australia
Moleculin Biotech at H.C. Wainwright conference: aml hope builds - Investing.com
MBRX: Annamycin's Phase III AML trial shows triple the remission rate of control with zero cardiotoxicity - TradingView
Moleculin Presentation from H.C. Wainwright Conference Now Available On-Demand - The Manila Times
A biotech’s clinical update goes online before New York investor meetings - Stock Titan
Moleculin Biotech (MBRX) Holds Above $0.77 as Biotech Sector Watches Key Resistance at $0.81Trend Following Picks - siam.in
Moleculin Biotech Stock Price Forecast. Should You Buy MBRX? - StockInvest.us
MBRX Should I Buy - Intellectia AI
Why Did MBRX Stock Climb 14% Today? - Stocktwits
Moleculin Biotech (NASDAQ:MBRX) Participates in Virtual Investor "What This Means" Segment Hosted by JTC Team - ACCESS Newswire
Moleculin Biotech Updates Investors with New Presentation - TipRanks
Moleculin (NASDAQ: MBRX) posts investor presentation online - Stock Titan
MOLECULIN BIOTECH, INC. : H.C. WAINWRIGHT CUTS TARGET PRICE TO $3 FROM $22 - webull.com
Moleculin Biotech Inc. (MBRX) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Moleculin Biotech Is Maintained at Buy by HC Wainwright & Co. - Moomoo
Enterprise value to revenue forward of Moleculin Biotech, Inc. – LSE:0K2H - TradingView
Moleculin CEO, Walter Klemp, Participates in the Virtual Investor 'Why Now” On-Demand Conference - The Manila Times
Signal Proxy Intelligence Recommends AGAINST Moleculin Biotech, Inc. Executive Compensation Ahead of Oct. 9, 2026 Annual Meeting (NASDAQ:MBRX) - kitv.com
Moleculin (NASDAQ: MBRX) CEO invests $400K of own cash - Stock Titan
What date does Moleculin Biotech's (MBRX) report EarningsEarnings Calendar & Announcement - Zacks Investment Research
Moleculin (MBRX) Chart: Rises 0.41% to $0.59 for the Current Session; Price Levels: the Supplied Trading Band Runs From $0.56 to $0.62 in the Latest SessionBPI Bear Confirmed - vinanet.vn
Moleculin (MBRX) Results Breakdown: EPS Comes in Below Forecast in the Current Update; Trading Response - vinanet.vn
Moleculin (MBRX) Daily Snapshot: Climbs 0.49% to $0.61 for the Current Session; the Price Remains Bounded by the Supplied Support and Resistance at the CloseMcClellan Oscillator - vinanet.vn
Maxim Group Maintains Moleculin Biotech(MBRX.US) With Buy Rating, Cuts Target Price to $2 - Moomoo
Moleculin Biotech Releases Q2 2026 Financial Results - AlphaStreet
Moleculin Biotech (NASDAQ: MBRX) seeks reverse split and plan changes at 2026 meeting - Stock Titan
Moleculin Biotech 2Q Research and Development Expenses $5.5M >MBRX - Moomoo
Moleculin Biotech expects cash position to fund operations into Q1 2027 - TradingView
Form 8K Moleculin Biotech Inc For: 14 August By Investing.com - Investing.com Canada
Moleculin Biotech Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of Pivotal MIRACLE Trial - The Manila Times
Moleculin Biotech reports Q2 2026 loss of $7.6M, cash $7.3M; MIRACLE trial interim efficacy positive - TradingView
Moleculin Biotech Reports Second Quarter 2026 Financial - GlobeNewswire
Moleculin Biotech Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Moleculin Biotech (NASDAQ: MBRX) advances AML trial but warns on cash - Stock Titan
Moleculin Biotech, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
MBRX Q1 2026 Earnings: Wider-than-Expected Loss Reflects Clinical-Stage InvestmentLow Growth Earnings - vinanet.vn
Moleculin Biotech (MBRX): CVI and Heights disclose 1.86M-share, 9.9% ownership - Stock Titan
Q1 2025 Moleculin Biotech Inc Earnings Call Transcript - GuruFocus
Moleculin Biotech, Inc. Actuals & Estimates (NASDAQ:MBRX) - TradingView
Moleculin Biotech Inc expected to post a loss of $1.54 a shareEarnings Preview - TradingView
Moleculin Biotech (MBRX) stake capped at 4.99% under Intracoastal warrants - stocktitan.net
Moleculin Biotech, Inc. (MBRX) CFO buys 293,333 shares and 879,999 warrants - Stock Titan
Moleculin Biotech, Inc. (MBRX) CEO adds stock and 1.6M Series I warrants - Stock Titan
Moleculin Biotech (MBRX) CSO buys common stock and Series I Warrants - stocktitan.net
Price to sales forward of Moleculin Biotech, Inc. – LS:A41SET - TradingView
Moleculin reports promising preliminary phase II/III data for leukaemia drug Annamycin - Indian Pharma Post
Moleculin Biotech Raises $9.3 Million Equity; Signs Placement, Purchase and Lock-Up Agreements - TradingView
Form 424B5 Moleculin Biotech Inc For: 3 August By Investing.com - Investing.com South Africa
Moleculin Biotech Reports Positive Pivotal Phase 2/3 Trial Results for Annamycin in AML - The Indian Practitioner
Weekly Recap: MIRACLE Part A response rates and $0.75 unit offering - TradingView
Moleculin Biotech, Inc. SEC Filing (Aug 3, 2026) - Stock Titan
Moleculin Biotech Inc (MBRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.05%
1.96%
자본화:
|
볼륨(24시간):